Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiko Imamura

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Scientific Reports|July 25, 2022
Cellular analysis of SOD1 protein-aggregation propensity and toxicity: a case of ALS with slow progression harboring homozygous SOD1-D92G mutationMasanori Sawamura, Keiko Imamura, Rie Hikawa, et al.
Scientific Reports|October 11, 2016
Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neuronsKeiko Imamura, Naruhiko Sahara, Nicholas M Kanaan, et al.
Eclinicalmedicine|December 5, 2022
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trialKeiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
NPJ Vaccines|March 29, 2020
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model miceHiroki Takeuchi, Keiko Imamura, Bin Ji, et al.
JCI Insight|April 22, 2024
Phototoxicity avoidance is a potential therapeutic approach for retinal dystrophy caused by EYS dysfunctionYuki Otsuka, Keiko Imamura, Akio Oishi, et al.
BMJ Open|December 5, 2019
Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patientsKeiko Imamura, Yuishin Izumi, Haruhiko Banno, et al.
Nature Communications|July 12, 2018
A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse modelNaomi Tsuburaya, Kengo Homma, Tsunehiko Higuchi, et al.
Japanese Journal of Radiology|December 3, 2015
The essence of the Japan Radiological Society/Japanese College of Radiology Imaging GuidelineYasuyuki Yamashita, Sadayuki Murayama, Masahiro Okada, et al.
Clinical Science (London, England : 1979)|February 20, 2019
<i>MiR-33a</i> is a therapeutic target in SPG4-related hereditary spastic paraplegia human neuronsFumiko Nakazeki, Itaru Tsuge, Takahiro Horie, et al.
BMJ Open|October 26, 2024
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) studyKeiko Imamura, Yuishin Izumi, Naohiro Egawa, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Scientific Reports|July 25, 2022
Cellular analysis of SOD1 protein-aggregation propensity and toxicity: a case of ALS with slow progression harboring homozygous SOD1-D92G mutationMasanori Sawamura, Keiko Imamura, Rie Hikawa, et al.
Scientific Reports|October 11, 2016
Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neuronsKeiko Imamura, Naruhiko Sahara, Nicholas M Kanaan, et al.
Eclinicalmedicine|December 5, 2022
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trialKeiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
NPJ Vaccines|March 29, 2020
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model miceHiroki Takeuchi, Keiko Imamura, Bin Ji, et al.
JCI Insight|April 22, 2024
Phototoxicity avoidance is a potential therapeutic approach for retinal dystrophy caused by EYS dysfunctionYuki Otsuka, Keiko Imamura, Akio Oishi, et al.
BMJ Open|December 5, 2019
Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patientsKeiko Imamura, Yuishin Izumi, Haruhiko Banno, et al.
Nature Communications|July 12, 2018
A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse modelNaomi Tsuburaya, Kengo Homma, Tsunehiko Higuchi, et al.
Japanese Journal of Radiology|December 3, 2015
The essence of the Japan Radiological Society/Japanese College of Radiology Imaging GuidelineYasuyuki Yamashita, Sadayuki Murayama, Masahiro Okada, et al.
Clinical Science (London, England : 1979)|February 20, 2019
<i>MiR-33a</i> is a therapeutic target in SPG4-related hereditary spastic paraplegia human neuronsFumiko Nakazeki, Itaru Tsuge, Takahiro Horie, et al.
BMJ Open|October 26, 2024
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) studyKeiko Imamura, Yuishin Izumi, Naohiro Egawa, et al.
Pageof 9